You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
A new analysis has provided evidence that adjuvant lung cancer immunotherapy benefits those with lingering ctDNA, but not necessary those without.
The deal comes on the heels of a colorectal cancer-focused drug-discovery alliance that the German companies formed in early 2019.
The funds will support the companies' efforts to develop tests for predicting NSCLC patients' response to immunotherapy.
The companies will develop tissue-based companion diagnostics for Amgen's investigational treatment AMG 510 for non-small cell lung cancer.
The company plans to submit a companion diagnostic version of its sequencing-based liquid biopsy test Guardant360 to various regulatory bodies.
The approval will allow clinicians to identify NSCLC patients with ROS1 fusion genes who could benefit from treatment with Rozlytrek.
Palmetto has expanded the local coverage determination for the Guardant360 liquid biopsy assay to be used with the majority of advanced solid tumors.
The company has multiple companion diagnostics partnerships in the works, with new tests on the way in 2020, and new plans for next-generation sequencing.
The company will use its InVisionFirst-Lung test to study resistance mutations in patients treated with Pfizer's ALK inhibitor lorlatinib.
The grant will co-fund a year-long project to validate Biofidelity's chemistry to detect mutations used to guide non-small-cell lung cancer treatment.
A new study finds that three dimensional facial scans may be able to aid in diagnosing rare genetic diseases.
The Lancet and the New England Journal of Medicine have retracted two COVID-19 papers due to concerns about the data used in their analyses.
Lawmakers plan to introduce a bill that aims to prevent the theft of US-funded research, according to the Wall Street Journal.
In Science this week: analysis of ancient Caribbean islanders' genomes suggests at least three waves of migration into the region, DNA barcoding of microbial spores, and more.